Overview

A Phase 1, Two Part Study Investigating the Safety, Tolerability and Pharmacokinetics of KNX100 in Healthy Volunteers

Status:
Not yet recruiting

Trial end date:
2022-09-15

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability of KNX100 administered orally as a single ascending dose and as multiple ascending doses in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Kinoxis Therapeutics Pty Ltd

Collaborator:

National Institute on Drug Abuse (NIDA)